Deadline for manuscript submissions: 31 August 2021Print Special Issue Flyer (35)
Department of Anesthesia & Intensive Care. Istituto Nazionale Tumori - IRCCS - Fondazione Pascale, Via Mariano Semmola 80100, Napoli, Italy
Interests: General anesthesia, Preclinical research, Translational research, Pulmonary ventilation, Intensive care, medical education, Pain medicine, Opioids
Department of Anesthesia and Critical Care. Ospedale Pediatrico Bambino Gesù IRCCS, Piazza S. Onofrio 4, 00165, Rome, Italy
Interests: General anesthesia, Pediatric anesthesia, Intensive care, Medical education, Paine medicine, Opioids, Acupuncture
Within a few months, we have witnessed a profound revolution in medical knowledge as medicine has been enriched with a new chapter. The scientific world has focused its attention on the phenomenon and to date, at the end of September 2020, a PubMed search with the word 'COVID-19' results in approximately 60,000 publications.
The most important clinical and pathological element of this disease is pneumonia. It can result in acute respiratory distress syndrome (ARDS) characterized by hypoxemic respiratory failure of different degrees with bilateral lung infiltrates. The pathogenic mechanism that produces the COVID-induced ARDS (CARDS) is particularly complex. It involves a direct viral attack on pulmonary and endothelium cells combined with immune-mediated inflammation. The so-called 'cytokine storm' is expressed as a high release of proinflammatory cytokines such as interleukin-6 (IL-6), tumor necrosis factor α (TNF-α), IL-1β, IL-8, and IL-12 as well as interferon-gamma inducible protein (IP10), macrophage inflammatory protein 1A (MIP1A), and monocyte chemo attractant protein 1 (MCP1). This excessive immune reaction in the host can produce extensive tissue damage with dysfunctional coagulation.
Treatment of CARDS represents a clinical challenge. Although the non-invasive ventilation can improve oxygenation, limiting the work of the respiratory muscles and preventing the onset of the patient self-inflicted lung injury, CARDS management often requires tracheal intubation and invasive mechanical ventilation.
In this context of the pandemic, therapeutic implications concern various professional fields, including but not limited to intensivists, pulmonologists, infectious diseases specialists. Again, fascinating is the diagnostic aspect of the CARDS in terms of imaging, pathology, and laboratory medicine. Yet, translational and clinical research must necessarily act as a driving force for identifying new therapeutic strategies.
On these premises, the Special Issue can be expected to be of interest to a variety of medical subdisciplines. Also, virologists, and biologists, may be interested in submitting their research. The psychological aspects related to the isolation of patients is a further area of interest of the Special Issue. Similarly, as an important question concerns the impact of the disease on organ function in survivors, not only respiratory but also cardiovascular, renal, neurological functions and pain, we are strongly interested in studies focused on the sequelae of the disease.
In the present Special Issue, we aim to collect a number of important manuscripts for both helping readers to get an up-to-date on the topic and for stimulating further research. Thus, we invite original research articles and state-of-the-art reviews focused on current knowledge and future perspectives on CARDS. In particular, we are interested in preclinical and clinical research on the pathophysiology of CARDS as well as, clinical research on diagnosis, and therapy. Summary data expressed as narrative reviews, and evidence-based medicine analysis are welcome. Interesting and innovative case reports and case series are welcome too. Finally, recognized experts on the subject are invited to propose editorials or perspective articles.
SARS-CoV-2, COVID-19, COVID-19-induced acute respiratory distress syndrome, Pathophysiology, Diagnostic tools, Imaging Therapeutic perspectives, Psychological impact, Sequelae of COVID-19, Pain
Manuscripts should be submitted online by submit system. Manuscripts can be submitted until the deadline. All papers will be peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Original articles, case reports or comprehensive reviews are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website. Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a double-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Signa Viate is an international peer-reviewed open access journal published by MRE Press. As of January 2021, Signa Vitae will change to a bimonthly journal. Please visit the Instructions for Authors page before submitting a manuscript.The Article Processing Charge (APC) for publication in this open access journal is $1200. We normally offer a discount greater than 30% to all contributors invited by the Editor-in-Chief, Guest Editor (GE) and Editorial board member. Submitted papers should be well formatted and use good English.
Tailored sedation in critically ill COVID-19 patients based on lung damage, and pharmacokinetic and pharmacodynamic proﬁles
Online publish date: 29 June 2021
Science Citation Index Expanded (SciSearch) Created as SCI in 1964, Science Citation Index Expanded now indexes over 9,200 of the world’s most impactful journals across 178 scientific disciplines. More than 53 million records and 1.18 billion cited references date back from 1900 to present.
Journal Citation Reports/Science Edition Journal Citation Reports/Science Edition aims to evaluate a journal’s value from multiple perspectives including the journal impact factor, descriptive data about a journal’s open access content as well as contributing authors, and provide readers a transparent and publisher-neutral data & statistics information about the journal.
Chemical Abstracts Service Source Index The CAS Source Index (CASSI) Search Tool is an online resource that can quickly identify or confirm journal titles and abbreviations for publications indexed by CAS since 1907, including serial and non-serial scientific and technical publications.
IndexCopernicus The Index Copernicus International (ICI) Journals database’s is an international indexation database of scientific journals. It covered international scientific journals which divided into general information, contents of individual issues, detailed bibliography (references) sections for every publication, as well as full texts of publications in the form of attached files (optional). For now, there are more than 58,000 scientific journals registered at ICI.
Geneva Foundation for Medical Education and Research The Geneva Foundation for Medical Education and Research (GFMER) is a non-profit organization established in 2002 and it works in close collaboration with the World Health Organization (WHO). The overall objectives of the Foundation are to promote and develop health education and research programs.
Scopus: CiteScore 0.5(2019) Scopus is Elsevier's abstract and citation database launched in 2004. Scopus covers nearly 36,377 titles (22,794 active titles and 13,583 Inactive titles) from approximately 11,678 publishers, of which 34,346 are peer-reviewed journals in top-level subject fields: life sciences, social sciences, physical sciences and health sciences.
Embase Embase (often styled EMBASE for Excerpta Medica dataBASE), produced by Elsevier, is a biomedical and pharmacological database of published literature designed to support information managers and pharmacovigilance in complying with the regulatory requirements of a licensed drug.